My conversation with Mark left me both excited and uneasy. I explained the difference between traditional “generative” AI, which analyzes vast datasets to summarize trends or findings, and the more unsettling new wave, “Agentic AI.”
As a physician and molecular biologist, I’ve marveled at AI’s ability to transform medicine. Scanning and summarizing journal articles, augmenting care GI Genius, which assists in colonoscopies by spotting lesions our eyes might miss. However, a friend of mine was nearly tricked by a fake email that appeared to be from her boss - a chilling reminder of how easily criminals can exploit “agentic AI” that doesn’t just analyze; it acts.
This duality of helpful innovation on the one hand and grave danger on the other makes me believe we must tread carefully, keeping our wits about us.
You can find the entire conversation here.
Looking for more information?
Will Artificial Intelligence Replace Human Psychiatrists?
The Brave New World of AI: From Shoe Design to Colonoscopies
Henry I. Miller, MS, MD
Henry I. Miller, MS, MD, is the Glenn Swogger Distinguished Fellow at the American Council on Science and Health. His research focuses on public policy toward science, technology, and medicine, encompassing a number of areas, including pharmaceutical development, genetic engineering, models for regulatory reform, precision medicine, and the emergence of new viral diseases. Dr. Miller served for fifteen years at the US Food and Drug Administration (FDA) in a number of posts, including as the founding director of the Office of Biotechnology.
